Lupus & antiphospholipid syndrome
Systematic literature review of intravenous immunoglobulin use in non-renal and non-hematologic systemic lupus erytehmatosus
Authors' conclusion
After reviewing the experience of the use of IVIGs in extra-renal and extra-hematologic SLE patients, this treatment is demonstrated to be useful in refractory cases, especially in pulmonary, cardiac or neuropsychiatric complications with a good safety profile.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients with no renal and no hematologic manifestations35 articles
- Participants
- 198 patients
- Outcome
- Clinical response to IVIG
Methodological detailsPRISMA principles
- PRISMA principles
Main finding
As reported in the abstract
Clinical response to IVIG (non-renal, non-hematologic SLE)
Clinical response
167
84.3%
Complete response
62
31.3%
Partial response
105
53%
Further findings
Complete response by manifestation (individualized data)
- Respiratory problems (5): complete response in all cases
- all
- Cardiac involvement (18): complete response
- 82.4%
- Neuropsychiatric manifestations (18): complete response
- 53.8%
Safety
Adverse events
- Patients with adverse events
- 40 (20.2%)
- Most of them mild
Severe adverse events
- Severe adverse events
- 2 (1%)
Original publication
Systematic literature review of intravenous immunoglobulin use in non-renal and non-hematologic systemic lupus erytehmatosus. Lupus. Published 6 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →